Abstract
Hydroxypyridinones (HPs) are a family of N-heterocyclic metal chelators, which have been an attractive target in the development of a variety of new pharmaceutical drugs, due to their high metal chelating efficacy/specificity and easy derivatization to tune the desired biological properties. In fact, along the last decades, hydroxypyridinone derivatives, but mostly 3-hydroxy-4-pyridinone (3,4-HP), have been intensively used in drug design, following either a multitarget approach, in which one chelating unity is extrafunctionalized (hybridized) to enable the interaction with other important specific biological sites, or a polydenticity approach, in which more than one chelating moiety is conveniently attached to one scaffold, to increase the metal chelating efficacy. This review represents an update of the most recent publications (2014-2016) in mono-HP hybrids, namely as potential anti-Alzheimer's drugs, inhibitors of metalloenzymes and anti-microbials, and also polychelating compounds (poly- HP), in view of potential application, such as anti-microbial/biostatic agents, luminescent biosensors or diagnostic agents.
Keywords: Hydroxypyridinones, 3-hydroxy-4-pyridinones, iron chelators, anti-neurodegeneratives, bioinorganic medicinal chemistry.
Current Medicinal Chemistry
Title:Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update
Volume: 25 Issue: 1
Author(s): Sílvia Chaves, Luca Piemontese, Asha Hiremathad and M. Amélia Santos*
Affiliation:
- Centro de Quimica Estrutural, Instituto Superior Tecnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa,Portugal
Keywords: Hydroxypyridinones, 3-hydroxy-4-pyridinones, iron chelators, anti-neurodegeneratives, bioinorganic medicinal chemistry.
Abstract: Hydroxypyridinones (HPs) are a family of N-heterocyclic metal chelators, which have been an attractive target in the development of a variety of new pharmaceutical drugs, due to their high metal chelating efficacy/specificity and easy derivatization to tune the desired biological properties. In fact, along the last decades, hydroxypyridinone derivatives, but mostly 3-hydroxy-4-pyridinone (3,4-HP), have been intensively used in drug design, following either a multitarget approach, in which one chelating unity is extrafunctionalized (hybridized) to enable the interaction with other important specific biological sites, or a polydenticity approach, in which more than one chelating moiety is conveniently attached to one scaffold, to increase the metal chelating efficacy. This review represents an update of the most recent publications (2014-2016) in mono-HP hybrids, namely as potential anti-Alzheimer's drugs, inhibitors of metalloenzymes and anti-microbials, and also polychelating compounds (poly- HP), in view of potential application, such as anti-microbial/biostatic agents, luminescent biosensors or diagnostic agents.
Export Options
About this article
Cite this article as:
Chaves Sílvia , Piemontese Luca , Hiremathad Asha and Santos Amélia M. *, Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update, Current Medicinal Chemistry 2018; 25 (1) . https://dx.doi.org/10.2174/0929867324666170330092304
DOI https://dx.doi.org/10.2174/0929867324666170330092304 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enantiopure 1,2,3-Triazolyl-β-amino Acids via Click Cycloaddition Reaction on Racemic Alkynyl Precursors Followed by Separation of Stereoisomers
Current Topics in Medicinal Chemistry Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization
Current Pharmaceutical Design Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders
Current Drug Targets Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Complexities of Glucuronidation Affecting In Vitro-In Vivo Extrapolation
Current Drug Metabolism Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
CNS & Neurological Disorders - Drug Targets Design, Synthesis, and Screening of Hybrid Benzothiazolyl-Oxadiazoles as Anticonvulsant Agents
Letters in Drug Design & Discovery Transient Receptor Potential Vanilloid 1 and Xenobiotics
CNS & Neurological Disorders - Drug Targets An Overview of EEG Seizure Detection Units and Identifying their Complexity- A Review
Current Signal Transduction Therapy Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Preterm Birth and the Risk of Neurodevelopmental Disorders - Is There a Role for Epigenetic Dysregulation?
Current Genomics